SCIENTIFIC REPORTS

OPEN

Genome engineering in the yeast pathogen *Candida glabrata* using the CRISPR-Cas9 system

Ludovic Enkler, Delphine Richer, Anthony L. Marchand, Dominique Ferrandon & Fabrice Jossinet

Received: 09 May 2016

Accepted: 05 October 2016

Published: 21 October 2016

Among *Candida* species, the opportunistic fungal pathogen *Candida glabrata* has become the second most common causative agent of candidiasis in the world and a major public health concern. Yet, few molecular tools and resources are available to explore the biology of *C. glabrata* and to better understand its virulence during infection. In this study, we describe a robust experimental strategy to generate loss-of-function mutants in *C. glabrata*. The procedure is based on the development of three main tools: (i) a recombinant strain of *C. glabrata* constitutively expressing the CRISPR-Cas9 system, (ii) an online program facilitating the selection of the most efficient guide RNAs for a given *C. glabrata* gene, and (iii) the identification of mutant strains by the Surveyor technique and sequencing. As a proof-of-concept, we have tested the virulence of some mutants *in vivo* in a *Drosophila melanogaster* infection model. Our results suggest that *yps11* and a previously uncharacterized serine/threonine kinase are involved, directly or indirectly, in the ability of the pathogenic yeast to infect this model host organism.

Due to the growing population of patients with weakened immune systems and to modern medical practices, such as the widespread use of catheters or of antibacterials and antifungals^{1–3}, the incidence of fungal infections has increased at an alarming rate in the past two decades. Recent estimates suggest that about 1.2 billion people worldwide suffer from a fungal infection⁴. Human fungal infections account for more deaths annually than either tuberculosis or malaria, most of them caused by species belonging to four genera of fungi: *Aspergillus*, *Candida*, *Cryptococcus*, and *Pneumocystis*⁵. Among *Candida* species, the opportunistic fungal pathogen *Candida glabrata*, a nondimorphic, haploid budding yeast, has become the second most common causative agent of candidiasis in the world. Whereas *C. albicans* ranks first in isolation frequency, *C. glabrata* is more resistant to antifungal therapy and is associated with higher mortality^{6,7}. As a result, *C. glabrata* has become a major public health concern during the past two decades. This reinforces the need to develop innovative therapeutic strategies to circumvent its high rates of resistance to azole antifungal compounds⁵.

The development of novel strategies requires a heightened understanding of *C. glabrata* infection. Indeed, whereas *C. albicans* aggressively attacks the host, *C. glabrata* seems to have developed a process based on a 'stealth-like' approach. Actually, key features of *C. albicans* pathogenicity, such as the formation of hyphae, mating, and the secretion of proteinases, have no equivalent in *C. glabrata*. Since its sequenced genome places it phylogenetically closer to *S. cerevisiae* than to *C. albicans*⁸, it has been proposed that the ability of *C. glabrata* to infect humans has evolved independently from that of other *Candida* species^{9,10}. *C. glabrata* presents peculiar features related to cell wall organization such as an exceptionally high number of genes encoding adhesion-like glycosylphosphatidylinositol (GPI)-anchored proteins¹¹ or the implication of GPI-anchored aspartyl proteases (a.k.a. yapsins) in the infection process^{12,13}. These features represent key virulence factors, with roles in the high tolerance to azole drugs⁷, in the adhesion to host cells or in survival inside macrophages (reviewed in¹⁴). The functional annotation of the genome of *C. glabrata* has also revealed the loss of specific genes, such as those needed for galactose, phosphate, nicotinic acid or allantoin metabolism^{9,15,16}.

Despite the characterization of these specific traits, the molecular mechanisms underlying *C. glabrata* infectivity are far from being completely understood. Unfortunately, few molecular tools and resources are available to explore its biology in comparison to those accessible for the *S. cerevisiae* model organism¹⁷. Among the techniques available to investigate gene function in living organisms, genetic approaches (gene disruption/

Architecture et Réactivité de l'ARN, UPR9022 du CNRS, Université de Strasbourg, Institut de biologie moléculaire et cellulaire du CNRS, 15 rue René Descartes, 67084, Strasbourg, France. Correspondence and requests for materials should be addressed to L.E. (email: l.enkler@ibmc-cnrs.unistra.fr) or F.J. (email: f.jossinet@ibmc-cnrs.unistra.fr)

replacement, RNA interference...) have been extensively employed. Systems like homologous recombination or Tn7-based genome-wide random insertion mutagenesis have already been successfully applied to *C. glabrata*^{18,19}. The recent discovery of the CRISPR-Cas9 system in bacteria and archaea has provided a new and extremely efficient approach to inactivate gene function²⁰. In this system, a Cas9 endonuclease is guided to specific genomic locations by a short single-guide RNA (sgRNA). Cas9 cleaves double-stranded DNA in a site-specific manner, and thereby activates the double strand break repair machinery (a.k.a. Non Homologous End Joining repair (NHEJ)), resulting in insertions or deletions (indels) that ultimately disrupt the targeted locus. Whereas the CRISPR-Cas9 system has initially been selected during evolution to perform gene disruption in bacteria, several groups have extended its application to RNA interference or *in situ* labeling^{21–23}. Today, the CRISPR-Cas9 system is successfully applied to numerous organisms, from bacteria²⁴ to human²⁵ and animals²⁶ through protozoan parasites²⁷ and fungal pathogens^{28–30}.

Here, we have established an efficient CRISPR-Cas9 system in *C. glabrata* to generate loss-of-function mutants through the NHEJ repair pathway. The system relies on a plasmid that expresses Cas9 from a *S. cerevisiae* or a *C. glabrata* promoter, which is transformed into strains that express sgRNAs under the control of either *S. cerevisiae* or *C. glabrata* promoters. We further demonstrate that this system can be used to increase the efficiency of homologous recombination in *C. glabrata*. Some of the mutant strains generated by this approach were further used to study colonization and infection in an invertebrate model^{31,32}. Namely, the targeted genes were: (i) a GPI-anchored aspartyl protease involved in the infection process of *C. glabrata* and (ii) a putative serine/threonine kinase of *C. glabrata*³³. Interestingly, we report that the corresponding mutants were less virulent in the *D. melanogaster* model and thus that these two genes should be involved, directly or indirectly, in the infection process of *C. glabrata in vivo*. Accordingly, this CRISPR-Cas9 system is powerful to assess the potential role of candidate genes in *C. glabrata* infectivity in this mini-host model and presumably in other infection models.

Results

Engineering of a CRISPR-Cas9 strain. For the development of the CRISPR-Cas9 system in *C. glabrata*, we took advantage of the well studied Δ HTL strain (Supplementary Table S1)³⁴. This triple auxotrophic strain (*his3*, *trp1* and *leu2*) has been extensively studied for persistence in mice, for the identification of novel antifungal tolerance genes, for testing antifungal compounds, and for investigating its phagocytosis by immune cells^{18,34,35}. Although RNA polymerase II promoters from *S. cerevisiae* can be easily used in *C. glabrata*^{36,37}, RNA expression is prone to species-specific regulations due to discrepancies in A- and B-boxes location in the upstream region of RNA gene³⁸. Therefore, for sgRNAs expression, we used a pRS315 vector developed for *S. cerevisiae* expression under *S. cerevisiae* SNR52 promoter (*pSNR52*)³⁹ and we also engineered another pRS315 vector bearing the RNA polymerase III promoter of the nuclear *C. glabrata* *RNAH1* gene (*pRNAH1*) followed by the tRNA Tyr 2 terminator (*tTY2*) (Fig. 1A, Supplementary Fig. S1 and Supplementary Table S2).

For CAS9 expression, we used the CRISPR-Cas9 system developed by DiCarlo and colleagues in *S. cerevisiae*³⁹. CAS9 was expressed from a centromeric p414 vector under the *S. cerevisiae* translational elongation factor EF-1 alpha (*TEF1*) promoter (plasmid named p414-CAS9(*TEF1*), Supplementary Table S2). We first checked whether CAS9 expression under the *S. cerevisiae* *TEF1* promoter (*pTEF1*) was affecting *C. glabrata* fitness. After the transformation of *C. glabrata* with the p414-CAS9(*TEF1*) vector, we monitored its average generation time in SCGlc 2% liquid media by measuring its growth over a period of 48 hours. The comparison of the doubling time of the Δ HTL + CAS9(*TEF1*) strain to that of the Δ HTL strain revealed that the constitutive expression of CAS9 in *C. glabrata* delays its average generation time by a factor of 3.5 (323.6 min vs 91.2 min; $p < 0.0001$) (Supplementary Fig. S3). In yeasts, a longer generation time and loss of fitness can be attributed to many factors including nuclear accumulation of a protein, metabolic disturbance or nutrient limitation. In the case of the Δ HTL + CAS9(*TEF1*) strain, we hypothesized that CAS9 expression under the *pTEF1* promoter might be too strong for *C. glabrata* fitness and that this caused nuclear accumulation of the protein Cas9. To overcome this, we decided to substitute the *pTEF1* promoter with the endogenous promoter of the cytochrome C isoform1 protein of *C. glabrata* (plasmid named pRS314 – CAS9(*CYC1*), Supplementary Table S2). In *S. cerevisiae*, this promoter has been shown to induce a weak and ubiquitous expression of genes under its dependency, with up to 48 times less expression as compared to the *pTEF1* promoter⁴⁰. However, this alternative approach only led to a small reduction of the generation time, as compared to the Δ HTL + CAS9(*TEF1*) strain (292.8 min vs 323.6; $p = 0.264$), which was still 3.2 times slower than the Δ HTL strain (292.8 min vs 91.2 min; $p = 0.009$) (Supplementary Fig. S3). This indicates that CAS9 expression hampers *C. glabrata* fitness. To circumvent this problem, we generated the Δ HTL strain expressing sgRNA prior to pRS314-CAS9(*CYC1*) transformation in every further assay, since expression of sgRNA alone does not impede *C. glabrata* fitness (data not shown).

CRISPR-Cas9 gene disruption by indels. We then tested the ability to create indels in *C. glabrata* by targeting the disruption of the *ADE2* gene, known to be a good phenotypic marker because of the red phenotype of *ade2* cells (Fig. 1B). With the help of our bioinformatics tool CASTING, we designed two sgRNAs targeting the *ADE2* locus: sgADE2.1 and sgADE2.3 (Fig. 1A,C, Supplementary Fig. S2 and Mat & Met). We have tested all possibilities by combining sgRNAs expressed either under a *S. cerevisiae* (*pSNR52*) or a *C. glabrata* promoter (*pRNAH1*) with CAS9 expressed either from a *S. cerevisiae* heterologous promoter (*pTEF1*) or from a *C. glabrata* endogenous promoter (*pCYC1*) (Fig. 1D). As expected, when yeasts were plated on appropriate synthetic media, a strong red phenotype was observed upon *ADE2* disruption (Fig. 2A), whereas strains expressing CAS9 or sgRNA alone displayed the expected white phenotype. To further assess *ADE2* disruption, we performed a Surveyor assay on strains expressing CAS9 alone or in combination with sgADE2.1 or sgADE2.3. To better detect indels, we designed two primers (see Supplementary Table S3); the *ADE2*-Fwd primer is respectively localized 271nt and 198nt upstream of the sgADE2.1 and sgADE2.3 disruption sites. Likewise, the *ADE2*-Rev primer is respectively localized 339nt and 412nt downstream of the sgADE2.1 and sgADE2.3 target sites. No indels were detected

Figure 1. Design of CRISPR-Cas9 in *C. glabrata* and schematic of *ADE2* disruption. (A) CAS9 expression was done either with the p414 vector engineered by DiCarlo and colleagues (39) under the *S. cerevisiae* *TEF1* promoter (*pTEF1*) or with the pRS314 under the *C. glabrata* *CYC1* promoter (*pCYC1*). sgRNAs were cloned in a pRS315 and expressed either under the RNA Pol III promoters of *S. cerevisiae* *SNR52* (*pSNR52*) or *C. glabrata* *RNAH1* (*pRNAH1*). (B) Simplified scheme of adenine biosynthesis. Cells deprived of *ADE2* display a red phenotype due to the accumulation of a red pigment. (C) Two target sequences localized in 5' of the *ADE2* were chosen for gene disruption: sgADE2.1 and sgADE2.3. Arrowheads indicate Cas9 cleavage sites. (D) Workflow of the sequential transformations done for sgRNA and CAS9 expression in *C. glabrata* and description of the following experiments.

when CAS9 was expressed alone in *C. glabrata* (Fig. 2B,C left lane). In contrast, we observed efficient indels in each strain co-expressing CAS9, with any of the two sgRNAs targeting *ADE2* (Fig. 2B,C middle and right lanes). To characterize at the nucleotide level the events that led to *ADE2* disruption, we sequenced the region in which indels were expected to occur. We then made two interesting observations: (i) when disruption was induced by sgADE2.1 under the control of a *C. glabrata* promoter, NHEJ in *C. glabrata* mostly lead to insertion of only one nucleotide (essentially a T) at the cutting site (whether CAS9 was expressed under a *C. glabrata* or a *S. cerevisiae* promoter; Fig. 2D upper panel), and (ii) NHEJ elicited by sgADE2.3 expressed under a *S. cerevisiae* promoter often generated large insertions of nucleotides, and this was predominantly observed when co-expressed with CAS9(*TEF1*) which mimics a *S. cerevisiae* system (Fig. 2D lower panel). These results suggest that for efficient gene disruption by NHEJ repair in *C. glabrata*, CAS9 should be expressed under the *pCYC1* promoter in combination with sgRNAs expression under the *pRNAH1* promoter.

CRISPR-Cas9 targeted homologous recombination. To get effective homologous recombination (HR) in *C. glabrata* routinely, inserted DNA fragments need to bear a minimum of 500 bp of homology domain (HD) at both 5' and 3' ends of the sequence¹⁸. We asked whether HD length could be decreased by disrupting the *ADE2* locus through the co-expression of CAS9(*CYC1*) and sgADE2.1 in the presence of a template repair DNA. We tested two cassettes: one of 57 bp composed of three TAG stop codons in the three reading frames (XTAG) and another one of 1,202 bp encompassing 385nt of the *HIS3* promoter and the *HIS3* gene of *C. glabrata* (*cgHIS3*) (Fig. 3A,B and Supplementary Fig. S4A,B). Twenty or 200 bp of *ADE2* HD were added at the 5' and 3' ends of each cassette to study the effect of HD length on HR (see Supplementary Methods). We transformed *C. glabrata* strains expressing sgADE2.1 with either CAS9 alone or CAS9 supplemented with 1 µg of XTAG or *HIS3* PCR products and we measured the recombination frequency in each case. After screening and sequencing, we observed a better recombination frequency for XTAG insertion with 4 times more recombination events taking place when disruption was elicited by coexpression of CAS9 with sgADE2.1, compared to expression of CAS9 alone. The recombination rate was even more efficient (8-fold higher) when 200 bp of HD were used, as compared to 20 bp (Fig. 3C). To ensure that XTAG was indeed inserted at the disruption site in *ADE2*, we sequenced clones after insertion and documented efficient HR (Supplementary Fig. S4A). We also observed an increase in HR for the *HIS3* cassette, with up to a 3-fold increase when 20 bp HD were used. Unexpectedly, the frequency was not different whether we used 20 or 200 bp of HD and was similar to the frequency of XTAG with only 20 bp of HD after Cas9 cleavage (Fig. 3C, Supplementary Fig. S4B). This suggests that directed gene disruption facilitates HR

Figure 2. Efficient CRISPR-Cas9 gene disruption of the *ADE2* locus. (A) Drop test of Δ HTL, Δ HTL + sgADE2.1 or sgADE2.3, Δ HTL + CAS9 (*TEF1* or *CYC1*), Δ HTL + sgADE2.1 or sgADE2.3 + CAS9 (*TEF1* or *CYC1*) on SCGlc 2% and SCGlc 2% without leucine (-L) or tryptophan (-W) or both -L-W. Plates were incubated 2 days at 30 °C. (B,C) Indels in *ADE2* cells were monitored by Surveyor assay in Δ HTL strain compared to the Δ HTL + CAS9 (*CYC1*), Δ HTL + sgADE2.1 + CAS9 (*CYC1*) or Δ HTL + sgADE2.3 + CAS9 (*CYC1*). (D) Events leading to *ADE2* disruption were monitored by sequencing each strain and by comparing to the *in silico* constructs. Insertions and deletions are shown in green. For each deleted strain, 6 different clones were tested.

and that the length of the homology region required for HR seems to have a greater impact with short inserts. In any case, we have demonstrated here that the CRISPR-Cas9 system allows achieving efficient recombination in *C. glabrata* with only 20 or 200 bp of HD, as compared to the recommended 500 bp.

Figure 3. Recombination efficiency in *C. glabrata* using targeted gene disruption with CRISPR-Cas9.

(A) Workflow of *C. glabrata* expressing sgADE2.1 transformation with CAS9 (CYC1) and either XTAG or HIS3 dsDNA bearing either 20 or 200 bp of homology domain (HD). (B) For homologous recombination, XTAG and HIS3 cassettes were inserted at the sgADE2.1 cut site in ADE2. Sequences of XTAG and HIS3 are listed in Supplementary Fig. 3. For each cassette, we appended either 20 or 200 bp of HD corresponding to the sequence around sgADE2.1 cutting site. (C) ΔHTL strain expressing the sgADE2.1 was transformed with a dsDNA cassette XTAG or HIS3 with or without the pRS314-CAS9 (CYC1). To evaluate efficient recombination at the ADE2 locus, we checked integration of XTAG and HIS3 by PCR after selection of mutants on SCGlc 2% -L-W plates. In each experiment, we tested HR with cassettes bearing 20 or 200 bp-long flanking regions. * $p < 0.05$, ** $p < 0.01$, nd: not different, each bar represents mean values of $n > 200$ clones, SEM are shown.

C. glabrata Cas9-generated mutant strain to study *C. glabrata* infection in *D. melanogaster*.

Recent studies highlighted the use and advantages of *Drosophila melanogaster* as a model organism to study virulence and host adaptation^{17,31,32}. This model is based on two *D. melanogaster* strains, a WT immuno-competent strain (A5001) in which the Toll pathway senses fungal infections, and an immuno-compromised strain which lacks the MyD88 Toll adapter, *MyD88*⁴¹. In WT flies, the response mediated by the Toll pathway acts as a barrier against fungal infection and controls yeast development, independently of the known antifungal peptides Drosomycin and Metchnikowin and may involve other *Drosophila* immune induced molecules^{31,42}. In contrast, *MyD88* mutant flies succumb rapidly after fungal infection and this is correlated to fungal burden. Except for phagocytosis, no adequate immune response is mounted in these mutant flies³¹. We used this infection model to test two mutants of *C. glabrata* generated by Cas9 (Supplementary Methods and Supplementary Figs S2 and S5A,B). The first is the *yps11* strain in which the *YPS11* gene was disrupted. This gene encodes an aspartyl protease that was shown to be upregulated during macrophage internalization¹². The second strain is mutant for the *CAGL0K04301g* gene, which codes for a putative serine/threonine kinase in *C. glabrata*. The latter is homologous to the mitochondrial protein *FMP48* in *S. cerevisiae*⁴³ and to a putative kinase implicated in virulence and mouse kidney colonization *HSL1* in *C. albicans*^{33,44}. Since the Candida Genome Database describes this gene as an “Uncharacterized ORF”⁴⁵, we decided to rename it *VPK1* for Validated Protein by Knock-out 1. We tested the subsequent *vpk1* and *yps11* strains for *in vitro* culture and infection analysis.

Prior to any experiment, *C. glabrata* cells were grown in YPD for 24 h at 30 °C in order to get rid of both vectors that allow expressing the sgRNAs or CAS9 (data not shown). We first monitored the behavior of the Δ HTL *C. glabrata* strain (Supplementary Table S1) grown in liquid culture until the exponential phase was reached and compared it with the two different strains we engineered.

Many *C. glabrata* strains deleted in genes implicated in the cell wall integrity pathway display sensitivity to caffeine, CaCl₂ and other salts at pH 7.5 or pH 5.5^{12,13,46–48}. We therefore tested the *ade2*, *yps11* and *vpk1* strains along with the Δ HTL strain for cell wall-related phenotypes. In any of the tested conditions, we did not observe differences in growth nor in colony size for the Δ HTL, *yps11* or *vpk1* strains, which suggests that *YPS11* and *VPK1* do not play major role in cell wall integrity maintenance (Fig. 4A). Likewise, we did not detect any significant discrepancy in the average generation time of these four strains grown in SCGlc 2% media when compared to that of the Δ HTL strain (Fig. 4B). To our surprise, the *ade2* strain displayed susceptibility to caffeine in every condition tested and to ZnCl₂ at pH 7.5 at 30 and 37 °C, although to a lesser extent. Growth of *ade2* was slightly altered on YPD, NaCl and CaCl₂ at pH 5.5 and 7.5 both at 30 and 37 °C. This emphasizes that the quadruple auxotrophy (Δ HTLA) might impact either the Mpk1-mediated cell wall integrity pathway or more deeply the metabolism of amino acids.

To test the possibility to use Cas9-engineered *C. glabrata* strains to study the infection process in *Drosophila*, our strategy was to disrupt *YPS11* or *VPK1*, to get rid of both expressing plasmids, and then to sequence deleted loci prior to infection (Fig. 5A). *In vivo*, we first ascertained that clean injury was not affecting fly survival; as expected, no colonies grew on YPD plates supplemented with streptomycin when fly extracts were plated (Fig. 5B,C). Then, we asked to what extent fly survival was affected by infection with Δ HTL or Δ HTL + Cas9. After 96 hours of infection, 75 and 71.4% of *MyD88* flies succumbed by *C. glabrata* Δ HTL and Δ HTL + Cas9 respectively (Fig. 5B). This correlates with a constant increase in fungal load as observed by colony-forming units (CFU) realized at 0–24–48 and 72 hours post-infection (Fig. 5C). Infection of WT A5001 flies with Δ HTL and Δ HTL + Cas9 yielded similar results as a mock-infection (clean injury after 96 hours) and was not associated with any fungal growth (data not shown). Next, we compared fly survival after infection with Δ HTL, *yps11* or *vpk1* cells. *MyD88* flies infected with the Δ HTL strain succumbed faster to the infection (time for death of 50% of the flies [LT50] was about 110 hours), while flies infected with the *yps11* strain were killed slower (LT50 about 130 hours), but nevertheless faster than *vpk1* flies (LT50 about 180 hours) (Fig. 5D). Inoculation of Δ HTL, *yps11* or *vpk1* in A5001 WT flies however, led roughly to 80% of survival which is in accordance with what is expected in immuno-competent flies (Fig. 5B,D). To confirm that mortality was associated with increasing fungal load, we also measured CFUs at different time points. *vpk1* grew as efficiently as the Δ HTL strain in the host *MyD88* flies, whereas *yps11* appeared to proliferate somewhat slower (Fig. 5E).

To further confirm these results, we sequenced the *yps11* and *vpk1* strains after infection to ensure that the observed survival rates were indeed resulting from infection by the different disrupted strains. In every case, we retrieved the same mutations, thus indicating that the strains used for infection were indeed responsible for the differing survival rates we observed (Supplementary Fig. S5C,D). The results reported here are unlikely to be caused by second-site mutations, as we used three independently-generated mutants for each targeted gene in survival experiments. Finally, we also generated an additional mutant strain for *vpk1* by homologous recombination, which yielded an insertion of the *HIS3* gene in the *vpk1* locus. This mutant strain (*vpk1::HIS3*) displayed a decreased virulence in survival assays, although the NHEJ-generated CRISPR-Cas9 mutants were somewhat even more resistant to the infection (Supplementary Fig. S6). This latter difference might be accounted for by the fact that the HR mutant is no longer auxotrophic for histidine.

A major antifungal host defense remaining in the *MyD88* flies is the cellular arm, which can be impaired by saturating the phagocytic apparatus with injected non-degradable latex beads (LTX). As expected, LTX-injected *MyD88* flies succumbed much more rapidly to Δ HTL infection (LT50 about 24 hours; Fig. 5F). Interestingly, the NHEJ *vpk1* strain also killed flies faster (LT50 about 48 hours), yet not as rapidly as the Δ HTL strain. However, the difference in the killing rate of *vpk1* was reduced with respect to the Δ HTL strain, and was never higher than 48 hours, instead of 72 hours in non LTX-injected *MyD88* flies. Thus, *vpk1* appears to be somewhat more virulent when the cellular defenses of the host are ablated.

Discussion

In this study, we have developed a CRISPR-Cas9 system in *C. glabrata* and have shown easy and efficient gene disruption by indels, as well as gene recombination by directed homologous recombination. Using *D. melanogaster* as a model of infection, we have demonstrated that CRISPR-Cas9 is a suitable tool to engineer *C. glabrata*, disrupt any specific gene and then study its impact during the infection process. This is, to our knowledge, the first example of the CRISPR-Cas9 genetic tool applied to the opportunistic pathogen *C. glabrata*.

Currently, the *C. glabrata* toolbox is being expanded, but still lacks several techniques such as Tet-regulable library of essential genes, GFP-tagged or yeast two-hybrid strains libraries¹⁷. The CRISPR-Cas9 engineering system was part of these missing tools. This is of great importance since *C. glabrata* has a dominant NHEJ DNA repair pathway that makes gene replacement difficult⁴⁹. Nevertheless, *C. glabrata* gene replacement or gene deletion by insertion of cassette can be achieved via homologous recombination with large flanking regions. Schwarzmuller and colleagues have recently set up a gene deletion library using 500 bp HD¹⁸, and were able to disrupt roughly 13% of all *C. glabrata* genes. To increase the number of deleted genes, we hypothesized that generating a double strand DNA cut with Cas9 endonuclease might favor the homology-directed DNA repair. Using two types of disrupting cassettes (*XTAG* and *HIS3*) and two different HD (20 and 200 bp) (Fig. 3 and Supplementary Fig. 4), we showed that HR can be efficiently accomplished both with short and large fragments. Our results also showed that the size of flanking regions is important for short but not large fragments (Fig. 3).

Figure 4. Phenotypic characterization of the Δ HTL, *ade2*, *yps11* and *vpk1* strains. (A) Drop test of each strain engineered on YPD plates at pH5.5 and 7.5 supplemented in NaCl (500 mM), ZnCl₂ (10 mM), CaCl₂ (100 mM) or caffeine (7.5 mM). Plates were stored for 1 day at 30 or 37 °C except for YPD plates supplemented with ZnCl₂ stored for 3 days. (B) Average generation time of Δ HTL, *ade2*, *yps11* and *vpk1* strains monitored during growth in SCGlc 2% liquid medium. Numbers are mean generation time for each strain. n = 3, SEM are shown.

To test the efficiency of the homologous recombination in *C. glabrata*, two options were conceivable: (i) the ability to get revertants through the reinsertion of the gene to its original locus after Cas9 cut, or (ii) the ability to knock-out the target gene through the insertion of a selection marker. We chose the second option for two main reasons. First, we wanted to compare the efficiency of this recombination with the NHEJ assays. Second, it was in our interest to test the feasibility of an alternative way to knock-out genes, which was helpful to further characterize mutants during *Drosophila* infections, and with the clear advantage to positively select mutants.

We have shown that Δ HTL strain expressing CAS9 has an increased generation time as compared to the Δ HTL strain (Supplementary Fig. S3). When *Drosophila* flies were challenged with Δ HTL + CAS9 (*CYC1*), survival rates were similar to the Δ HTL strain (Fig. 5B). This is in contradiction with the slow doubling time

Figure 5. Study of *C. glabrata* infection in *D. melanogaster* after genome engineering by the CRISPR-Cas9 system. **(A)** Scheme of Cas9-directed gene disruption in *C. glabrata* prior to *D. melanogaster* infection. After sequential transformation of sgRNA- and CAS9 (CYC1)-expressing vectors, targeted gene disruption was checked by sequencing. Vectors were then lost by growing yeasts overnight in liquid SCGlc 2% media. **(B)** Survival curves of immuno-competent A5001 flies and immuno-compromised MyD88 flies after infection with clean prick (cp), ΔHTL strain or ΔHTL + Cas9. Survival are shown as percentage of surviving flies. ** $p < 0,05$ when compared to survival curve of MyD88 + cp or A5001 + cp. **(C)** Colony Forming Units (CFU) of cp and *C. glabrata* ΔHTL or ΔHTL + Cas9 after infection of *D. melanogaster* A5001 and MyD88 flies. **(D)** Infection of A5001 and MyD88 flies with the ΔHTL strain and strains disrupted for YPS11 and VPK1. **** $p < 0,0001$ when compared to survival curve of MyD88 + ΔHTL; ns, not significant. **(E)** CFU experiments related to infections performed in **(D)**. Drosophila drawing is the work of B. Nuhanen, and was obtained from <https://commons.wikimedia.org/wiki/File:Drosophila-drawing.svg>, and is licensed under a CC BY-SA license (<https://creativecommons.org/licenses/by-sa/3.0/deed.en>). **(F)** Infection of latex (LTX) beads-injected A5001 and MyD88 flies with the ΔHTL strain or the NHEJ-*vpk1* mutant.

displayed in liquid SCGlc 2% -W media. CFU tests after infection clearly demonstrated that ΔHTL + CAS9 was growing at the same rate as a ΔHTL strain in the host fly (Fig. 5C). This can be explained by the fact that tryptophan is available in *Drosophila* and thus no selection pressure is exerted to maintain the CAS9 expressing plasmid; in these conditions, yeasts recovered their native ΔHTL generation time.

Among the numerous models available to study infection by yeasts, the most common ones are macrophages, mice and *Drosophila*^{12,31,32,34,35,50–52}. Stress tolerance and adaptation can be monitored in any of these three models, and *in vitro* as well. Up to now, *Drosophila*, and to a lower extent mouse, seem to be more suitable to study systemic infection. This is partly due to the fact that fungal infection kills immunosuppressed *Drosophila*, in contrast to mice in which only fungal colonization of organs can be assessed^{32,34,52}. In addition, there are no ethical or cost-related

concerns when working with *Drosophila*. Accordingly, the *Drosophila* model described by Quintin and colleagues³¹ seemed to be the adequate model to study *C. glabrata* pathogenesis with our CRISPR-Cas9 system.

We note that we did not observe a perfect correlation between fungal titer *in vivo* and virulence, as measured in survival assays. For instance, the *vpk1* NHEJ-CRISPR-Cas9 mutant is less virulent than the Δ HTL strain, yet displays a similar fungal load. By the same token, *yps11* appears to be more virulent than *vpk1* even though its titer in flies is lower. One possibility is that *C. glabrata* mutants may differentially adhere or colonize distinct organs. It will be interesting to determine whether *vpk1* apparent proliferation is restricted to a specific organ. Alternatively, one significant difficulty lies in the interpretation of CFU counts when survival curves display the shape observed in our experiments. Flies start to succumb early on, significantly already at 48 hours. Our experience with CFU counts once the flies have started dying from the infection is that these counts may be misleading, with errors introduced by sampling: flies about to die often yield high titers whereas flies bound to survive will display a low titer, as they may have managed to control the infection. Thus, a definitive conclusion will be reached only when this experiment has been repeated much more extensively than in the preliminary characterization reported here.

Several studies have focused on the yapsin genes and their role in *C. glabrata* pathogenicity^{12,13,51,53,54}. Yapsins form a family of 11 genes encoding putative GPI-linked aspartyl proteases, and named because of their structural similarities with *YPS* genes of *S. cerevisiae*¹². Some yapsin genes have been shown to be upregulated during internalization in macrophages (*YPS 2-4-8-9-10-11*) or in neutrophils (*YPS 1-2-5-6-8-9-10-11*)^{12,54}. In addition, yeasts lacking *YPS1* displayed a reduced dissemination into kidneys, liver and spleen during a 7-day infection in mice and were less associated with macrophages after 24 hours, whereas Δ *yps7* strain displayed a normal association with macrophages and dissemination into mice kidneys, liver and spleen¹². Pathogenicity was more reduced when *YPS1* and -7 or when *YPS1-11* were deleted. Nevertheless, these observations are tempered by the fact that Δ *yps1*, Δ *yps1-7* or Δ *yps1-11* cells are sensitive to NaCl at pH7.5, ZnCl₂ at pH5.5 and 7.5, CaCl₂ and KCl at pH7.5^{12,13}. In liquid stationary phase, loss of viability was observed for 3 of these strains and the presence of depressions on Δ *yps1-11* cell surfaces was a striking evidence for cell wall defects^{12,13}. Altogether, these observations point toward a more general defect at the level of cell wall composition, and the inability of these mutants to respond to environmental and intracellular stresses, rather than directly implicating yapsin genes in the infection process. In our analysis, we could not detect any cell wall-defect phenotype during growth test assays or generation time using the *yps11* strain (Fig. 4A,B). CFU assays showed a constant increase of the fungal burden during *yps11* cells infection and a reduced virulence in survival assays (Fig. 5D,E). This suggests that *YPS11* might not be involved in the regulation of cell wall composition, but more likely hinders the maturation or incorporation of proteases or other proteins at the cell wall that would be important for pathogenicity.

We named the *CAGL0K04301g* gene Validated Protein by Knock-out 1 (*VPK1*), because the Candida Genome Database describes it as uncharacterized ORF, and because our results validate it as a gene whose product impacts the infection process in *D. melanogaster* (Fig. 5D–F). Having in mind that the understanding of the role of *VPK1* needs further investigation, we would like to emphasize several observations that would suggest a direct or indirect role in the virulence of *C. glabrata*. Indeed, the *vpk1* mutant does regain some virulence in phagocytosis-impaired flies, which suggests that one of its function may be to counteract or circumvent the cellular immune response, as shown for *Pseudomonas aeruginosa* *rhlR* gene⁵⁵. *FMP48*, its homolog in *S. cerevisiae*, was reported to be a mitochondrial protein⁴³, the expression of which was induced by UV radiation and 8-methoxypsoralen treatment⁵⁶. *HSL1*, its homolog in *C. albicans*, is implicated both in the determination of morphology during the cell cycle³³, and in virulence and kidney colonization in a mouse model of systemic infection⁴⁴. With respect to *VPK1* in *C. glabrata*, caution should be taken in interpreting its function in the light of its yeasts counterparts, as the role of proteins can vary between organisms. Although sometimes homologs do share the same role in phylogenetically-related organisms like *YPS1* or *MSN2/4* in *S. cerevisiae*, *C. albicans* and *C. glabrata*^{9,57}, roles can be dramatically different in some cases, as exemplified by *SCH9* that regulates ribosome biogenesis, translation and entry into the G0 phase of *S. cerevisiae*, but controls chromosome segregation in *C. albicans*⁵⁸. Furthermore *VPK1* does not seem to be a mitochondrial protein, as we failed to identify a mitochondrial targeting sequence (data not shown).

To conclude, virulence-gene studies in relevant infection models is crucial to understanding fungal pathogenesis. The use of technologies such as CRISPR-Cas9, in combination with an invertebrate infection model like *Drosophila melanogaster*, will now allow simultaneous genes disruption in genome-wide genetic screens using sgRNA libraries. Such large-scale approaches will lead to the identification of the factors required directly or indirectly for *C. glabrata* virulence *in vivo*.

Material and Methods

Identification of CRISPR-Cas9 targets in the *C. glabrata* genome. To characterize the best CRISPR-Cas9 targets for a given *C. glabrata* gene, we have developed a dedicated bioinformatics tool. Named CASTING (for « CAS9 Targets IN Genomes »), it has been implemented in Python 2.7 and is mainly based on the library PyRNA provided by the RNA-Science-Toolbox project (<https://github.com/fjossinet/RNA-Science-Toolbox>). Using the complete *C. glabrata* CBS138 genome (NCBI BioProject PRJNA12376), extended with the new genes identified by Linde and colleagues⁵⁹, CASTING takes as input a gene name, a genomic location, or a user-defined sequence. In a first step, CASTING searches for all PAM motifs of the form NGG or NAG. In a second step, each motif is extended by 20 nt on its 5'-end. Among all these potential 23nt-long sequences, CASTING filters out sub-optimal sequences containing k-mers as described by Xie and colleagues⁶⁰. In a third step, CASTING restricts the candidates to the sequences with a GC content between 35% and 75%. For each remaining on-target sequence, CASTING delegates to the tool SeqMap the identification of its off-target sites⁶¹. All the on-target sites are then ranked according to the sgRNA activity predictive model proposed by Doench and colleagues⁶². CASTING has been made available online at <http://charn-ibmc.u-strasbg.fr:8080/casting.html>. The website is based on the

Python microframework Flask (<http://flask.pocoo.org>) and on the JavaScript libraries jQuery (<https://jquery.com>) and Bootstrap (<http://getbootstrap.com>).

Plasmids construction. All single-guide RNA sequences (sgRNA, see Supplementary Material S2) were cloned in a centromeric pRS315 vector under the control of *S. cerevisiae* SNR52 (*pSNR52*) or *C. glabrata* RNAH1 (*pRNAH1*) constitutive promoters (Supplementary Table S2 and Fig. 1A). Using the *Hind*III cloning site of pRS315, we cloned a cassette containing either the *pSNR52* or *pRNAH1* promoters, followed by a 46 bp sequence harboring two *Aar*I restriction sites, the structural guiding RNA and a *scTY2* or *cgTY2* terminator respectively (sequences are listed in Supplementary Fig. S1). Each sgRNA sequence was synthesized by Integrated DNA Technologies (IDT) as two 20 bp complementary single strand DNA oligomers flanked by 20 bp of homology to the *Aar*I-digested pRS315 (sgRNA sequences are shown in Supplementary Material S2). They were used at a final concentration of 10 μ M in Duplex buffer (100 mM potassium acetate, 30 mM HEPES pH7.5) and 50 pmoles of each strand were mixed and incubated at 94 °C for 2 min, then cooled 2 min at room temperature and finally kept at 4 °C before use. The dsDNA was then diluted 10 times in deionized water, 1 pmole was used with 1 μ g of *Aar*I-digested pRS315 and assembly was achieved by the Gibson assembly method (New England BioLabs).

Streptococcus pyogenes CAS9 was used in two different vectors. First, the p414-CAS9(*TEF1*) (AddGene) expresses CAS9 under the *S. cerevisiae* *TEF1* promoter (*pTEF1*)³⁹ (Fig. 1A and Supplementary Table S2). Second, we also produced our own CAS9 expressing vector based on a *C. glabrata* promoter (plasmid named pRS314-CAS9(*CYC1*)). To do so, we first cloned the CAS9 gene from the p414-CAS9(*TEF1*) plasmid into the pRS314 after a *Kpn*I/*Xba*I digestion. We then amplified the *C. glabrata* *CYC1* promoter (*pCYC1*) flanked with *Spe*I restriction sites and cloned it into the pRS314-CAS9 by the Gibson assembly method and by following manufacturer's instructions (Fig. 1A and Supplementary Table S2).

Fly strains. Stocks were raised on rich standard cornmeal-agar medium at 25 °C. *w* A5001 flies were used as wild-type throughout the whole experiments and *MyD88* mutant flies in the A5001 genetic background have been described previously⁴¹.

Survival experiments and statistical analysis. Female A5001 (WT) or *MyD88* mutant flies aged between 7 and 16 days were isolated in batches of 20–25 flies. WT and *MyD88* mutant flies were challenged by septic injury with a needle previously dipped into a solution of various *C. glabrata* strains grown to stationary phase (Δ HTL and derivatives) concentrated at an OD_{600nm} 15 in YPD. Vials containing infected flies were put in an incubator for 240 hours at 29 °C. After 96 h of incubation, flies were moved to new vials. Results are expressed as percentage of surviving flies at different time points post-infection. Each survival experiment is representative of at least two replicates done with three independent yeast colonies obtained by two independent disruption experiments. Statistical significance during survival experiments was calculated with the method of Mantel and Cox using the log-rank test (GraphPad PRISM6 software), and $p < 0.05$ was considered significant.

CFU experiments. During flies infection, three flies were taken at each time point post-infection in order to monitor *C. glabrata* replication. Flies were crushed in an Eppendorf using a 0.5 mL grinder pestles in 150 μ L of PBS 1x and 0.1% Tween 20. Appropriate dilutions were made for each time point in YPD, plated on YPD supplemented with streptomycin (50 μ g/mL) and incubated at 30 °C for 2 days.

References

- Almirante, B. *et al.* Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003. *J. Clin. Microbiol.* **43**, 1829–1835 (2005).
- Lin, M. Y. *et al.* Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-control study. *Antimicrob. Agents Chemother.* **49**, 4555–4560 (2005).
- Sandven, P. *et al.* Candidemia in Norway (1991 to 2003): results from a nationwide study. *J. Clin. Microbiol.* **44**, 1977–1981 (2006).
- Brown, G. D. *et al.* Hidden killers: human fungal infections. *Sci Transl Med* **4**, 1–9 (2012).
- Denning, D. W. & Bromley, M. J. Infectious Disease. How to bolster the antifungal pipeline. *Science* **347**, 1414–1416 (2015).
- Krcmery, V. & Barnes, A. J. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. *J. Hosp. Infect.* **50**, 243–260 (2002).
- Vale-Silva, L. A. & Sanglard, D. Tipping the balance both ways: drug resistance and virulence in Candida glabrata. **15**, 1–8 (2015).
- Dujon, B. *et al.* Genome evolution in yeasts. *Nature* **430**, 35–44 (2004).
- Roetzer, A., Gabaldón, T. & Schüller, C. From Saccharomyces cerevisiae to Candida glabrata in a few easy steps: important adaptations for an opportunistic pathogen. *FEMS Microbiology Letters* **314**, 1–9 (2010).
- Gabaldón, T. & Carreté, L. The birth of a deadly yeast: tracing the evolutionary emergence of virulence traits in Candida glabrata. *FEMS Yeast Res.* **16**, fov110 (2016).
- de Groot, P. W. J. *et al.* The cell wall of the human pathogen Candida glabrata: differential incorporation of novel adhesin-like wall proteins. *Eukaryotic Cell* **7**, 1951–1964 (2008).
- Kaur, R., Ma, B. & Cormack, B. P. A family of glycosylphosphatidylinositol-linked aspartyl proteases is required for virulence of Candida glabrata. *Proc. Natl. Acad. Sci. USA* **104**, 7628–7633 (2007).
- Bairwa, G., Rasheed, M., Taigwal, R., Sahoo, R. & Kaur, R. GPI (glycosylphosphatidylinositol)-linked aspartyl proteases regulate vacuole homeostasis in Candida glabrata. *Biochem. J.* **458**, 323–334 (2014).
- Kasper, L., Seider, K. & Hube, B. Intracellular survival of Candida glabrata in macrophages: immune evasion and persistence. *FEMS Yeast Res.* **15**, fov042 (2015).
- Kaur, R., Domergue, R., Zupancic, M. L. & Cormack, B. P. A yeast by any other name: Candida glabrata and its interaction with the host. *Curr. Opin. Microbiol.* **8**, 378–384 (2005).
- Gabaldón, T. *et al.* Comparative genomics of emerging pathogens in the Candida glabrata clade. *BMC Genomics* **14**, 623–638 (2013).
- Ho, H.-L. & Haynes, K. Candida glabrata: new tools and technologies-expanding the toolkit. *FEMS Yeast Res.* **15**, fov066 (2015).
- Schwarzmueller, T. *et al.* Systematic phenotyping of a large-scale Candida glabrata deletion collection reveals novel antifungal tolerance genes. *PLoS Pathog.* **10**, e1004211 (2014).
- Castano, I. *et al.* Tn7-based genome-wide random insertional mutagenesis of Candida glabrata. *Genome Res.* **13**, 905–915 (2003).

20. Hsu, P. D., Lander, E. S. & Zhang, F. Development and applications of CRISPR-Cas9 for genome engineering. *Cell* **157**, 1262–1278 (2014).
21. Qi, L. S. *et al.* Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. *Cell* **152**, 1173–1183 (2013).
22. Anton, T., Bultmann, S., Leonhardt, H. & Markaki, Y. Visualization of specific DNA sequences in living mouse embryonic stem cells with a programmable fluorescent CRISPR/Cas system. *Nucleus* **5**, 163–172 (2014).
23. Deng, W., Shi, X., Tjian, R., Lionnet, T. & Singer, R. H. CASFISH: CRISPR/Cas9-mediated *in situ* labeling of genomic loci in fixed cells. *Proc. Natl. Acad. Sci. USA* **112**, 11870–11875 (2015).
24. Jiang, W., Bikard, D., Cox, D., Zhang, F. & Marraffini, L. A. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. *Nat. Biotechnol.* **31**, 233–239 (2013).
25. Mali, P. *et al.* RNA-guided human genome engineering via Cas9. *Science* **339**, 823–826 (2013).
26. Nelson, C. E. *et al.* *In vivo* genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. *Science* **351**, 403–407 (2015).
27. Vinayak, S. *et al.* Genetic modification of the diarrhoeal pathogen *Cryptosporidium parvum*. *Nature* **523**, 477–480 (2015).
28. Fuller, K. K., Chen, S., Loros, J. J. & Dunlap, J. C. Development of the CRISPR/Cas9 System for Targeted Gene Disruption in *Aspergillus fumigatus*. *Eukaryotic Cell* **14**, 1073–1080 (2015).
29. Schuster, M., Schweizer, G., Reissmann, S. & Kahmann, R. Genome editing in *Ustilago maydis* using the CRISPR-Cas system. *Fungal Genetics and Biology* **89**, 3–9 (2015).
30. Vyas, V. K., Barrasa, M. I. & Fink, G. R. A *Candida albicans* CRISPR system permits genetic engineering of essential genes and gene families. *Science Advances* **1**, e1500248 (2015).
31. Quintin, J., Asmar, J., Matskevich, A. A., Lafarge, M.-C. & Ferrandon, D. The *Drosophila* Toll pathway controls but does not clear *Candida glabrata* infections. *J. Immunol.* **190**, 2818–2827 (2013).
32. Brunke, S. *et al.* Of mice, flies--and men? Comparing fungal infection models for large-scale screening efforts. *Dis Model Mech* **8**, 473–486 (2015).
33. Wightman, R., Bates, S., Amornrattanapan, P. & Sudbery, P. In *Candida albicans*, the Nim1 kinases Gin4 and Hsl1 negatively regulate pseudohypha formation and Gin4 also controls septin organization. *J. Cell Biol.* **164**, 581–591 (2004).
34. Jacobsen, I. D. *et al.* *Candida glabrata* persistence in mice does not depend on host immunosuppression and is unaffected by fungal amino acid auxotrophy. *Infection and Immunity* **78**, 1066–1077 (2010).
35. Mota, S. *et al.* *Candida glabrata* susceptibility to antifungals and phagocytosis is modulated by acetate. *Front Microbiol* **6**, 919 (2015).
36. Macreadie, I., Castelli, L., Mehra, R. & Winge, J. T. A. Heterologous gene expression and protein secretion from *Candida glabrata*. *Biotechnology and Applied Biochemistry* **19**, 265–269 (1994).
37. Zordan, R. E. *et al.* Expression plasmids for use in *Candida glabrata*. *G3 (Bethesda)* **3**, 1675–1686 (2013).
38. Marck, C. *et al.* The RNA polymerase III-dependent family of genes in hemiascomycetes: comparative RNomics, decoding strategies, transcription and evolutionary implications. *Nucl. Acids Res.* **34**, 1816–1835 (2006).
39. DiCarlo, J. E. *et al.* Genome engineering in *Saccharomyces cerevisiae* using CRISPR-Cas systems. *Nucl. Acids Res.* **41**, 4336–4343 (2013).
40. Mumberg, D., Müller, R. & Funk, M. Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds. *Gene* **156**, 119–122 (1995).
41. Tauszig-Delamasure, S., Bilak, H., Capovilla, M., Hoffmann, J. A. & Imler, J.-L. *Drosophila* MyD88 is required for the response to fungal and Gram-positive bacterial infections. *Nature Immunology* **3**, 91–97 (2001).
42. Clemmons, A. W., Lindsay, S. A. & Wasserman, S. A. An effector Peptide family required for *Drosophila* toll-mediated immunity. *PLoS Pathog.* **11**, e1004876 (2015).
43. Reinders, J., Zahedi, R. P., Pfanner, N., Meisinger, C. & Sickmann, A. Toward the complete yeast mitochondrial proteome: multidimensional separation techniques for mitochondrial proteomics. *J. Proteome Res.* **5**, 1543–1554 (2006).
44. Umeyama, T. *et al.* *Candida albicans* protein kinase C_{Hsl1p} regulates cell elongation and virulence. *Mol. Microbiol.* **55**, 381–395 (2005).
45. Binkley, J. *et al.* The *Candida* Genome Database: the new homology information page highlights protein similarity and phylogeny. *Nucl. Acids Res.* **42**, D711–D716 (2014).
46. Martin, H., Rodríguez-Pachón, J. M., Ruiz, C., Nombela, C. & Molina, M. Regulatory mechanisms for modulation of signaling through the cell integrity Slt2-mediated pathway in *Saccharomyces cerevisiae*. *J. Biol. Chem.* **275**, 1511–1519 (2000).
47. Krysan, D. J., Ting, E. L., Abeijon, C., Kroos, L. & Fuller, R. S. Yapsins are a family of aspartyl proteases required for cell wall integrity in *Saccharomyces cerevisiae*. *Eukaryotic Cell* **4**, 1364–1374 (2005).
48. Levin, D. E. Regulation of cell wall biogenesis in *Saccharomyces cerevisiae*: the cell wall integrity signaling pathway. *Genetics* **189**, 1145–1175 (2011).
49. Zhang, C., Meng, X., Wei, X. & Lu, L. Highly efficient CRISPR mutagenesis by microhomology-mediated end joining in *Aspergillus fumigatus*. *Fungal Genet. Biol.* **86**, 47–57 (2015).
50. Kasper, L. *et al.* Identification of *Candida glabrata* genes involved in pH modulation and modification of the phagosomal environment in macrophages. *PLoS ONE* **9**, e96015 (2014).
51. Bairwa, G. & Kaur, R. A novel role for a glycosylphosphatidylinositol-anchored aspartyl protease, CgYps1, in the regulation of pH homeostasis in *Candida glabrata*. *Mol. Microbiol.* **79**, 900–913 (2011).
52. Brieland, J. *et al.* Comparison of pathogenesis and host immune responses to *Candida glabrata* and *Candida albicans* in systemically infected immunocompetent mice. *Infection and Immunity* **69**, 5046–5055 (2001).
53. Rai, M. N., Balusu, S., Gorityala, N., Dandu, L. & Kaur, R. Functional Genomic Analysis of *Candida glabrata*-Macrophage Interaction: Role of Chromatin Remodeling in Virulence. *PLoS Pathog.* **8**, e1002863 (2012).
54. Fukuda, Y., Tsai, H.-F., Myers, T. G. & Bennett, J. E. Transcriptional profiling of *Candida glabrata* during phagocytosis by neutrophils and in the infected mouse spleen. *Infection and Immunity* **81**, 1325–1333 (2013).
55. Limmer, S. *et al.* *Pseudomonas aeruginosa* RhlR is required to neutralize the cellular immune response in a *Drosophila melanogaster* oral infection model. *Proc. Natl. Acad. Sci. USA* **108**, 17378–17383 (2011).
56. Dardalhon, M. L., Lin, W., Nicolas, A. & Averbeck, D. Specific transcriptional responses induced by 8-methoxypsoralen and UVA in yeast. *7*, 866–878 (2007).
57. Gagnon-Arsenault, I., Tremblay, J. & Bourbonnais, Y. Fungal yapsins and cell wall: a unique family of aspartic peptidases for a distinctive cellular function. *FEMS Yeast Res.* **6**, 966–978 (2006).
58. Varshney, N. *et al.* A surprising role for the Sch9 protein kinase in chromosome segregation in *Candida albicans*. *Genetics* **199**, 671–674 (2015).
59. Linde, J. *et al.* Defining the transcriptomic landscape of *Candida glabrata* by RNA-Seq. *Nucl. Acids Res.* **43**, 1392–1406 (2015).
60. Xie, S., Shen, B., Zhang, C., Huang, X. & Zhang, Y. sgRNAcas9: a software package for designing CRISPR sgRNA and evaluating potential off-target cleavage sites. *PLoS ONE* **9**, e100448 (2014).
61. Jiang, H. & Wong, W. H. SeqMap: mapping massive amount of oligonucleotides to the genome. *Bioinformatics* **24**, 2395–2396 (2008).
62. Doench, J. G. *et al.* Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. *Nat. Biotechnol.* **32**, 1262–1267 (2014).

Acknowledgements

The research in this paper has been published under the framework of the LABEX: ANR-10-LABX-0036_NETRINA. It was supported by the University of Strasbourg Institute for Advanced Study (USIAS) as part of a USIAS Fellowship (to F.J.), the CNRS and the Investissement d'Avenir Program Grant ANR-11-EQPX-0022. We would also like to thank Dr. Adrien Franchet, Miriam Yamba, Catherine Socha and Dr. Samuel Liégeois for their technical help with *Drosophila*.

Author Contributions

L.E. designed CRISPR-Cas9 system. A.M. made the CASTING bioinformatics tool. D.R. set up fly infection. L.E. and D.R. realized all experiments. L.E., F.J. and D.F. designed the experiments and F.J. wrote the paper. All authors reviewed the manuscript.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Enkler, L. *et al.* Genome engineering in the yeast pathogen *Candida glabrata* using the CRISPR-Cas9 system. *Sci. Rep.* **6**, 35766; doi: 10.1038/srep35766 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2016